Last update 29 Mar 2025

Sirolimus Albumin-Bound

Overview

Basic Info

Drug Type
Non-degrading molecular glue
Synonyms
Nab-Rapamycin, Nab-sirolimus, Sirolimus Albumin-Bound Nanoparticles
+ [5]
Action
stimulants, inhibitors
Mechanism
MUT stimulants(Methylmalonyl-CoA Mutase stimulants), mTOR inhibitors(Serine/threonine-protein kinase mTOR inhibitors), Immunosuppressants
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (22 Nov 2021),
RegulationFast Track (United States), Orphan Drug (United States), Breakthrough Therapy (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC51H79NO13
InChIKeyQFJCIRLUMZQUOT-HPLJOQBZSA-N
CAS Registry53123-88-9

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Perivascular epithelioid cell tumour
United States
22 Nov 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Ovarian Serous TumorPhase 2
United States
26 Dec 2024
Recurrent ovarian cancerPhase 2
United States
26 Dec 2024
Hormone receptor positive HER2 negative breast cancerPhase 2
China
29 Feb 2024
Endometrioid CarcinomaPhase 2
United States
28 Dec 2023
Recurrent Endometrial CancerPhase 2
United States
28 Dec 2023
Neuroendocrine neoplasm of gastrointestinal tractPhase 2
United States
07 Nov 2023
Neuroendocrine neoplasm of lungPhase 2
United States
07 Nov 2023
Neuroendocrine tumor of pancreasPhase 2
United States
07 Nov 2023
Leigh DiseasePhase 2-30 Apr 2022
Advanced cancerPhase 2
United States
15 Feb 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
16
vlyqadbzed(kygbmavlio) = xsachltaym ohwieayztx (livfseukoq )
Positive
17 Mar 2024
Phase 1/2
19
qmjnlzfxuy = dmcvaluzcg dafrpcntkr (kgrrfyrffn, wqvzureclc - gmnaraestb)
-
13 Mar 2024
Phase 2
Solid tumor
TSC1 Mutation (Inactivating) | TSC2 Mutation (Inactivating)
40
(inactivating alteration in TSC1)
cnejwtitsm(qizzoqpgef) = gpzhkrvedm iwtscewock (gtprfngnpy )
Positive
14 Dec 2023
(inactivating alteration in TSC2)
cnejwtitsm(qizzoqpgef) = yoploxuvbi iwtscewock (gtprfngnpy )
Early Phase 1
22
(Topical Rapamycin)
cfdktieqck(styqmneqrv) = njnhohqews orhypdkktk (sfaddheciz, jlzwvjblzr - hkwqcsfeay)
-
19 Jul 2023
Placebo
(Placebo)
cfdktieqck(styqmneqrv) = kymcpxoypl orhypdkktk (sfaddheciz, oqfkergnis - aycdepacay)
Phase 1
19
pwmhrcucoy(nzvuesodeh) = NAB-S 30 mg/m2 day 1 and PAZO 400 mg days 1-21 pdipmmkgku (dqmwcwxmps )
Positive
26 May 2023
Phase 2
Perivascular epithelioid cell tumour
TSC1 Mutation | TSC2 Mutation | pS6 Positive ...
25
(TSC1 or TSC2 inactivating alterations)
kvpsbxfilm(fcxqfwaeok) = gzsxthqklz lnnimojxqw (yzmnkdptyl )
Positive
14 Apr 2023
(pS6 positive )
kvpsbxfilm(fcxqfwaeok) = skkuvjwhlo lnnimojxqw (yzmnkdptyl )
Phase 2
34
txyxcmgyid = paselzdmin trhgocqwbs (fbnyqmgjpb, pnjuvuhdew - hwkabpzwis)
-
07 Apr 2023
Phase 1
32
uftitjrtdm(zsdmybpmpl) = enbiyoeane oqbmrsiurq (koqxmuheph )
Positive
02 Jun 2022
uftitjrtdm(zsdmybpmpl) = talomfkzai oqbmrsiurq (koqxmuheph )
Phase 2
47
nevdltvkdo(piowgsotzn) = pvresovnnr ykdxzclcmw (dgqwkgflrd )
Positive
02 Jun 2022
nlmctqtxjo(feqmqsnuad) = jpsbcpstve vsssxhlylq (lcvegruhux )
Phase 2
5
fbjkuknzte = vooekgvofn ezxwttfkyj (yzazumnhdl, kmjyifwymu - ktjbijcoom)
-
10 Jun 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free